Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial Results

Alimera Sciences to Release Second Quarter Fiscal Year 2013 Financial Results

PR Newswire

ATLANTA, Aug. 5, 2013

ATLANTA, Aug. 5, 2013 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM)
("Alimera"), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
today announced that it will release its second quarter fiscal year 2013
financial results after the market close on Monday, August 12, 2013. An
investor conference call will follow on the same day at 4:30 p.m. ET.

The conference call will be hosted by Dan Myers, President and Chief Executive
Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial
Officer.

To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or
(253) 237-1165 (international). A live webcast will be available on the
Investor Relations section of the corporate website at
http://www.alimerasciences.com.

A replay of the conference call will be available beginning August 12, 2013 at
7:30 p.m. ET and ending on August 18, 2013 by dialing (855) 859-2056 (U.S. and
Canada) or (404) 537-3406 (international), Conference ID Number: 24162060. A
replay of the webcast will be available on the corporate website for one week,
through August 18, 2013.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Presently Alimera is focused on
diseases affecting the back of the eye, or retina. Its primary product,
ILUVIEN, is the first product to provide a therapeutic effect of up to 36
months for patients with chronic DME considered insufficiently responsive to
available therapies.

Investor Contact:
ICR, LLC
John Mills
310-954-1105
John.Mills@icrinc.com

SOURCE Alimera Sciences, Inc.

Website: http://www.alimerasciences.com